scholarly journals Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan® -MGB probe genotyping method

2012 ◽  
Vol 4 (1) ◽  
pp. 109-112 ◽  
Author(s):  
PEIJIA LIU ◽  
HONGYAN LIANG ◽  
LI XUE ◽  
CHUN YANG ◽  
YANG LIU ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Genotyping Method ◽  
Mgb Probe

scholarly journals KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

2011 ◽  
Vol 104 (6) ◽  
pp. 1020-1026 ◽  
Author(s):  
N Knijn ◽  
L J M Mekenkamp ◽  
M Klomp ◽  
M E Vink-Börger ◽  
J Tol ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Colorectal Cancer Patients

scholarly journals KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Yuurin Kondo ◽  
Kazuhiko Hayashi ◽  
Kazuyuki Kawakami ◽  
Yukari Miwa ◽  
Hiroshi Hayashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Mutation Analysis ◽  
Kras Mutation

KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer

2010 ◽  
Vol 38 (12) ◽  
pp. 869-873 ◽  
Author(s):  
Giancarlo Troncone ◽  
Umberto Malapelle ◽  
Immacolata Cozzolino ◽  
Lucio Palombini
Keyword(s):  
Rectal Cancer ◽  
Mutation Analysis ◽  
Kras Mutation

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance

2012 ◽  
Vol 462 (1) ◽  
pp. 39-46 ◽  
Author(s):  
J. R. Dijkstra ◽  
D. A. M. Heideman ◽  
G. A. Meijer ◽  
J. E. Boers ◽  
N. A. ‘t Hart ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Quality Assurance ◽  
Cancer Cells ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Colon Cancer Cells

The clinical significance of KRAS monitoring in tumor tissues and blood of patients with pancreatic tumor.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 334-334 ◽  
Author(s):  
Fumiaki Watanabe ◽  
Koichi Suzuki ◽  
Kosuke Ichida ◽  
Yuji Takayama ◽  
Taro Fukui ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Treatment Outcome ◽  
Clinical Significance ◽  
Kras Mutation ◽  
Poor Prognosis ◽  
Pancreatic Tumor ◽  
Pancreatic Tumors ◽  
Tumor Tissues ◽  
Kras Status

334 Background: Monitoring of gene alterations in blood to track circulating tumor DNAs has been attempted for a clinical application. For example, KRAS monitoring in colorectal cancer provides a valuable biomarker for diagnosis and prediction of treatment outcome. While half of of colon cancer has RAS mutation, 90% of pancreatic cancer shows KRAS mutation, suggesting that most of pancreatic cancer is a good candidate for KRAS monitoring. In this study, we elucidated the clinical significance of KRASmonitoring in patients with pancreatic tumor during treatments. Methods: KRAS mutation in tumor tissues was determined by Scorpion ARMS or RASKET methods in 39 patients with pancreatic tumors. KRASmutation in blood (G12D, G12V, G12C, G12A, G12S, G12R, G13D, Q61L, Q61H) were investigated by using droplet digital polymerase chain reaction (ddPCR) in 24 patients treated with chemotherapy. Results: KRAS assessment in tumor tissues showed 33 patients with mutation and 6 patients without mutation. Thirty-three patients with mutation showed significantly poor prognosis of 49% in three years overall survival (OS) as compared with 100% in 6 patients with mutation (p=0.02). KRAS assessment in blood revealed that KRAS mutation was detected in 14 patients, but no detection was seen in 10 patients. Patients harboring KRAS mutation in blood exhibited significantly poor treatment outcome, including 12 patients with progressive disease, as compared with 10 patients without detection of mutation, including 6 patients with any treatment responses (stable disease in 4 patients and partial response in 2 patients, p=0.03). Fourteen patients with mutation in blood displayed poor prognosis of 20% in three years overall survival (OS), comparing to 69% in 10 patients without mutation in blood (p=0.06). Conclusions: KRAS status in tumor tissues was involved in prognosis; in addition, KRAS status in blood was implicated in treatment response of chemotherapy in patients with pancreatic tumor. KRAS monitoring in tumor tissues and blood provides useful information for the treatment strategy including chemotherapy in patients with pancreatic tumor.

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer

2012 ◽  
Vol 66 (8) ◽  
pp. 748-752 ◽  
Author(s):  
A. Pennycuick ◽  
T. Simpson ◽  
D. Crawley ◽  
R. Lal ◽  
G. Santis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mutation Analysis ◽  
Cell Lung Cancer ◽  
Kras Mutation ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Veronika Auner ◽  
Gernot Kriegshäuser ◽  
Dan Tong ◽  
Reinhard Horvat ◽  
Alexander Reinthaller ◽  
...  
Keyword(s):  
Mutation Analysis ◽  
Kras Mutation ◽  
High Sensitivity
Sign in / Sign up

Export Citation Format

Share Document